PAK6 and chronic myelogenous leukemia, BCR-ABL1 positive: Thus, our findings suggest that PAK6 may be an attractive therapeutic target due to its role in mediating the DNA damage response and governing multiple cell fates, including senescence and apoptosis, in the context of CML.